Debbies Gipson News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Debbies Gipson. Real-time updates on events, politics, business and more.

ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

January 9, 2023

/PRNewswire/ -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...

United States Alessia Fornoni Danielc Cattran Sharong Adler Fernandoc Fervenza Debbies Gipson

Source: prnewswire.com

ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

January 3, 2023

/PRNewswire/ -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...

United States Alessia Fornoni Danielc Cattran Sharong Adler Fernandoc Fervenza Debbies Gipson

Source: prnewswire.com

ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

January 3, 2023

Drs. Daniel C. Cattran and Fernando C. Fervenza join ZyVersas distinguished group of Scientific AdvisorsVAR 200 is a phase 2a-ready cholesterol e...

United States Alessia Fornoni Danielc Cattran Sharong Adler Fernandoc Fervenza Debbies Gipson

Source: businessinsider.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Debbies Gipson News Today

ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

Explore More Categories